We propose to leverage the multicenter international BVMC HHT recruitment network and the BVMC HHT database, in the next funding cycle, to characterize the risk of intracranial hemorrhage (ICH) in HHT patients with BAVMs and subgroups. To do so, we propose to expand the cohort of HHT BAVM patients, building on our established multicenter HHT BAVM database, the largest such cohort in the world. By doubling the cohort size and extending natural history follow-up, in Aim 1 we will increase precision of ICH rates in HHT BAVM patients overall, as well as subgroups of patients, and bring these estimates into a relevant range for clinical decision making.
In Aim 2, we propose to investigate genetic modifiers of HHT and BAVM phenotypes, building on preliminary evidence from the first BVMC cycle. We demonstrated that the ALK1 variant IVS3-35A>G is associated with HHT disease severity (presence of any organ AVMs), particularly in patients with an ENG mutation. We therefore postulate a second-hit or trans-heterozygosity hypothesis, which states that in addition to the disease-causing mutation, further reduction of function in the TGFBeta/BMP9 signaling pathway exacerbates HHT phenotypes. To test this hypothesis, we will evaluate common variants in pathway genes for their association with (1) """"""""any AVMs"""""""" and (2) BAVM risk in HHT patients and explore associations with ICH risk and other HHT severity phenotypes. We will utilize the initial BVMC HHT cohort (n=800, 200 BAVM) for discovery and the new second-cycle HHT cohort of 800 for replication.
Aim 3 is an exploratory aim, in which we plan to study vessel wall inflammation in BAVMs and ICH, using vessel wall imaging and tissue review for inflammatory cells and mediators. Project 3 participants will be recruited through 12 HHT Centers of Excellence, as well as the Patient Support Organization, HHT Foundation International (HHTFI). The HHT investigator group will continue to work closely with the HHTFI, as well as with the DMCC, leveraging the established DMCC web-based portal, data collection and management protocols in place. The BVMC HHT Project will continue to provide a much-needed and valuable resource for the clinical neurovascular community for the study of BAVMs in HHT.

Public Health Relevance

Hereditary Hemorrhagic Telangiectasia (HHT) is a rare genetic disorder characterized by arteriovenous malformations (AVMs) in the brain, lung, and liver. Clinical care for people with brain AVMs (BAVMs) remains a challenge, with devastating intracranial hemorrhage (ICH) an ongoing reality. Quantitative information about the risks of ICH from BAVMs in HHT patients is needed to guide clinical decision-making and therapeutic trials in these patients;Project 3 will characterize these risks, as well as their determinants.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Moy, Claudia S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Wellman, Rebecca J; Cho, Su Bin; Singh, Pratibha et al. (2018) G?q and hyper-phosphorylated ERK expression in Sturge-Weber syndrome leptomeningeal blood vessel endothelial cells. Vasc Med :1358863X18786068
Morrison, Melanie A; Payabvash, Seyedmehdi; Chen, Yicheng et al. (2018) A user-guided tool for semi-automated cerebral microbleed detection and volume segmentation: Evaluating vascular injury and data labelling for machine learning. Neuroimage Clin 20:498-505
Walcott, Brian P; Winkler, Ethan A; Zhou, Sirui et al. (2018) Identification of a rare BMP pathway mutation in a non-syndromic human brain arteriovenous malformation via exome sequencing. Hum Genome Var 5:18001
Pawlikowska, Ludmila; Nelson, Jeffrey; Guo, Diana E et al. (2018) Association of common candidate variants with vascular malformations and intracranial hemorrhage in hereditary hemorrhagic telangiectasia. Mol Genet Genomic Med 6:350-356
De la Torre, Alejandro J; Luat, Aimee F; Juhász, Csaba et al. (2018) A Multidisciplinary Consensus for Clinical Care and Research Needs for Sturge-Weber Syndrome. Pediatr Neurol 84:11-20
Meybodi, Ali Tayebi; Kim, Helen; Nelson, Jeffrey et al. (2018) Surgical Treatment vs Nonsurgical Treatment for Brain Arteriovenous Malformations in Patients with Hereditary Hemorrhagic Telangiectasia: A Retrospective Multicenter Consortium Study. Neurosurgery 82:35-47
Kasthuri, Raj S; Montifar, Megan; Nelson, Jeffrey et al. (2017) Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am J Hematol :
Zou, Xiaowei; Hart, Blaine L; Mabray, Marc et al. (2017) Automated algorithm for counting microbleeds in patients with familial cerebral cavernous malformations. Neuroradiology 59:685-690
Tang, Alan T; Choi, Jaesung P; Kotzin, Jonathan J et al. (2017) Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature 545:305-310
Strickland, Corinne D; Eberhardt, Steven C; Bartlett, Mary R et al. (2017) Familial Cerebral Cavernous Malformations Are Associated with Adrenal Calcifications on CT Scans: An Imaging Biomarker for a Hereditary Cerebrovascular Condition. Radiology 284:443-450

Showing the most recent 10 out of 49 publications